Research, Science and Treatments

Mesothelioma Treatment Guidelines Updated to Include Two New Agents

The National Comprehensive Cancer Network® (NCCN®) recently updated their treatment guidelines for malignant pleural mesothelioma.
The NCCN, a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
Their mesothelioma treatment guide book, which was […]



Anetumab Ravtansine Fails to Show Improvement of Progression-Free Survival in Mesothelioma

In a statement released on Sunday, Bayer announced that Anetumab ravtansine, its antibody-drug conjugate (ADC) tested in mesothelioma, has missed its primary endpoint failing to improve progression-free survival in mesothelioma patients.
“Malignant pleural mesothelioma is a very difficult-to-treat tumor, and we had hoped for a better outcome for patients,” said Robert LaCaze, Executive Vice President and […]


New Book Serves as Resource for Mesothelioma Researchers

Joseph R. Testa, PhD, of the Fox Chase Cancer Center has edited a newly published book titled “Asbestos and Mesothelioma” to serve as a resource for researchers and medical professionals in the field. Mary Hesdorffer, NP, Executive Director at the Meso Foundation co-authored one of the book’s chapters.
More information about the book follows:
“Asbestos and Mesothelioma,” […]


Genentech Halts Avastin Approval Filing for Mesothelioma

In 2015, data was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from a Phase III French study that demonstrated improved survival rates for patients who received bevacizumab (Avastin® Genentech, Inc.) in addition to the standard chemotherapy regimen of pemetrexed/cisplatin.
The outcome of the study prompted the independent French cooperative group and Genentech […]